Apc cy7 conjugated cd16 3g8

Manufactured by BioLegend

APC-Cy7-conjugated CD16 (3G8) is a monoclonal antibody that binds to the CD16 antigen. CD16 is a low-affinity Fc receptor expressed on natural killer cells, neutrophils, and macrophages. The antibody is conjugated to APC-Cy7, a fluorescent dye combination, for use in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Pe cy7 conjugated cd56 hcd56, by BioLegend (2 mentions) Apc conjugated cd45, by BioLegend (1 mentions) Fitc conjugated epcam, by BioLegend (1 mentions)

Close spelling variants of this product

APC-Cy7 (106 citations) CD16 (3G8, (20 citations) CD16-APC/Cy7 (17 citations) CD16-APC (14 citations) 3G8-APC (3 citations) CD16 APC-Cy7 (3G8; (2 citations)

2 protocols using apc cy7 conjugated cd16 3g8

Multiparametric Immunophenotyping of Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were immunophenotyped with the following fluorescent-labeled monoclonal antibodies (mAb) against: PE-Cy7-conjugated CD56 (HCD56; BioLegend, San Diego, CA), ECD/PE-CF594-conjugated CD3 (UCHT1; Beckman Coulter, Brea, CA), APC-Cy7-conjugated CD16 (3G8; BioLegend), Pacific Blue-conjugated CD45 (HI30; BioLegend), PerCP-Cy5.5/FITC-conjugated anti-human CD107a (LAMP-1) (H4A3; BioLegend), Pacific Blue/BV421-conjugated anti-human IFN-γ (4S.B3; BioLegend), FITC/Alexa Fluor 647-conjugated TNF-α (MAb11; BioLegend), FITC/PE-conjugated CD33 (P67.6; BD Biosciences), and APC-conjugated CD45 (HI30; BioLegend), FITC-conjugated EpCAM; (BioLegend). Phenotypic acquisition of cells was performed on the LSRII (BD Biosciences) and analyzed with FlowJo software (Tree Star Inc., Ashland, OR).

Vallera D.A., Felices M., McElmurry R., McCullar V., Zhou X., Schmohl J.U., Zhang B., Lenvik A.J., Panoskaltsis-Mortari A., Verneris M.R., Tolar J., Cooley S., Weisdorf D.J., Blazar B.R, & Miller J.S. (2016). IL-15 Trispecific Killer Engagers (TriKEs) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function. Clinical cancer research : an official journal of the American Association for Cancer Research, 22(14), 3440-3450.

+ Open protocol

+ Expand

Phenotyping of PBMCs and Ascites Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

PBMCs and ascites cells were phenotyped with the following fluorescent-labeled mAbs: BV421 or PE-Cy7 conjugated CD56 (HCD56; Biolegend), PE-CF594-conjugated CD3 (UCHT1; BD Biosciences), APC-Cy7-conjugated CD16 (3G8; Biolegend), PE-Cy7-conjugated KIR2DL1/S1/S3/S5 (HP-MA4; eBioscience), FITC-conjugated KIR2DL2/L3 (DX27; Biolegend), PE-conjugated KIR3DL1 (DX9: Biolegend), APCconjugated NKG2A (Z199; Beckman Coulter), BV605-conjugated CD57 (NK-1: BD), BV421-conjugated CD122 (TU27; Biolegend), PE-conjugated CD132 (TUGh4; BD), FITC-conjugated CD25 (M-A251; BD), PE-conjugated CD69 (FN50; Biolegend), FITC-conjugated CD107a (LAMP-1; H4A3; Biolegend), BV421-conjugated IFN-γ (4S.B3; Biolegend), AF647-conjugated TNFα (MAb11; Biolegend). Cells were stained, run on an LSRII (BD Biosciences), and analyzed with FlowJo software (Tree Star Inc.) as described previously (32 (link)).

Felices M., Chu S., Kodal B., Bendzick L., Ryan C., Lenvik A.J., Boylan K.L., Wong H.C., Skubitz A.P., Miller J.S, & Geller M.A. (2017). IL-15 super-agonist (ALT-803) enhances natural killer (NK) cell function against ovarian cancer. Gynecologic oncology, 145(3), 453-461.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!